Lora A. Tucker

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <i>MET</i> –Amplified and c-Met–Overexpressing Tumors, Irrespective of <i>MET</i> Pathway Dependence

Jieyi Wang, Mark G. Anderson, Anatol Oleksijew et al. · Clinical Cancer Research · 2016 · 140 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of Ras-Related Nuclear Protein, Targeting Protein for <i>Xenopus</i> Kinesin-like Protein 2, and Stearoyl-CoA Desaturase 1 as Promising Cancer Targets from an RNAi-Based Screen

Susan E. Morgan-Lappe, Lora A. Tucker, Xiaoli Huang et al. · Cancer Research · 2007 · 129 citations

Medicine, Molecular Biology, Oncology +15

Reducing agent-mediated precipitation of high-abundance plasma proteins

Scott E. Warder, Lora A. Tucker, Tamara J. Strelitzer et al. · Analytical Biochemistry · 2009 · 64 citations

Life Sciences, Biochemistry, Molecular Biology +14

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification

Jieyi Wang, Liliane Goetsch, Lora A. Tucker et al. · BMC Cancer · 2016 · 63 citations · Full text

Medicine, Cancer Biology, Oncology +16

Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases

Steve Fidanze, Scott Erickson, Gary T. Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 56 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +14